Medigene (MDGEF) Stock Price, News & Analysis

Company Overview

Medigene AG is a clinical-stage biopharmaceutical company headquartered in Planegg near Munich, Germany. The company focuses on the development of immuno-oncology therapies, including engineered T cell receptor (TCR) T cells, natural killer (NK) cells and dendritic cell (DC) vaccines for the treatment of cancer. Employing proprietary platforms for antigen identification and cell engineering, Medigene aims to create both personalized and off-the-shelf immunotherapies targeting a range of malignancies.

Medigene’s pipeline features programs in adoptive cell therapy, notably autologous TCR-based T cells designed to recognize tumor-specific antigens, as well as allogeneic NK cell products intended to enhance innate immune responses. In parallel, its DCOne platform leverages dendritic cells to prime T cells against hematological cancers. The company also explores combination strategies with immune checkpoint inhibitors to improve clinical outcomes and broaden the applicability of its therapies.

Established in 1994 as a spin-off from the Max Planck Institute, Medigene has expanded its research footprint through collaborations with partners in Europe, North America and Asia. Its leadership team comprises professionals with extensive experience in biotech research and development, translational medicine and regulatory affairs, supporting the advancement of its immunotherapy candidates through preclinical and clinical development.

Key Stats

• Today's Range: $0.10 to $0.10
• 50-Day Range: $0.10 to $0.10
• 52-Week Range: $0.10 to $1.30
• Volume: N/A
• Average Volume: 600 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:MDGEF
• CIK: N/A
• Web: www.medigene.com
• Phone: (989) 200-0330
• Fax: N/A
• Employees: 76
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A